The contraindicated populations for vebreltinib a targeted therapy drug, mainly include those allergic to the drug components, patients with severe hepatic and renal insufficiency, individuals at risk of specific drug-drug interactions, and pregnant or lactating women. The following groups of people may experience severe adverse reactions or have impaired treatment efficacy if taking this drug, and the risks must be evaluated strictly in accordance with the doctor’s advice.
Patients allergic to vebreltinib or its excipients
Allergic reactions may manifest as skin rashes, dyspnea, facial swelling and even anaphylactic shock. If a patient has a history of allergic symptoms after taking this drug, the drug must be discontinued immediately and medical attention sought. Patients should fully inform their doctors of their allergy history before medication use; skin tests or low-dose tests may be conducted when necessary to verify safety.
Patients with severe hepatic and renal insufficiency
vebreltinib is mainly metabolized by the liver and excreted by the kidneys.
Patients with hepatic insufficiency
Impaired metabolic capacity may lead to drug accumulation, increasing the risk of toxicity (e.g., elevated transaminases, jaundice).
Patients with renal insufficiency
Reduced excretion may cause excessively high drug concentrations, exacerbating renal damage or inducing other adverse reactions (e.g., edema, electrolyte imbalance).
For such patients, the dosage should be adjusted based on hepatic and renal function indicators (e.g., Child-Pugh classification, estimated glomerular filtration rate [eGFR]), or alternative treatment options should be selected.
Individuals at risk of specific drug-drug interactions
The combined use of vebreltinib with certain drugs may affect its efficacy or safety:
Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
May increase the plasma concentration of vebreltinib and raise the risk of adverse effects.
Potent CYP3A4 inducers (e.g., rifampicin, phenytoin):
May reduce the efficacy of vebreltinib.
Other targeted drugs or chemotherapeutic agents
Combined use may result in synergistic myelosuppression (e.g., thrombocytopenia) or gastrointestinal toxicity (e.g., diarrhea).
Patients should avoid taking other drugs without medical advice during the medication period and undergo regular monitoring of blood routine, hepatic and renal function.
Pregnant and lactating women
Pregnant women
Animal studies have shown that vebreltinib may cause fetal harm (e.g., malformations, growth restriction). Women of childbearing age should take effective contraceptive measures during medication use and continue contraception for at least one month after drug discontinuation.
Lactating women
The drug may be secreted into breast milk, posing unknown risks to infants; it is recommended to suspend breastfeeding during the medication period.
Other Precautions
Pediatric and adolescent patients
Safety data for this population is currently lacking, and the drug should be used with caution.
Patients with cardiovascular diseases
For those with a history of QT interval prolongation or heart failure, close monitoring of electrocardiograms and cardiac function is required.
Regular re-examinations during medication
Include blood routine, hepatic and renal function tests, and imaging assessments to facilitate prompt adjustment of the treatment plan as needed.
Summary
The principle of personalized medicine must be strictly followed for the contraindicated populations of vebreltinib. Doctors will assess the risks of medication use based on the patient’s medical history, test results and potential drug-drug interactions to ensure the safety and efficacy of treatment.
